威麦宁胶囊联合卡培他滨对于晚期乳腺癌患者的近期疗效和安全性评价

Short-term Efficacy and Safety of Weimaining Capsule Combined with Capecitabine in Patients with Advanced Breast Cancer

目的:观察威麦宁胶囊联合卡培他滨治疗晚期乳腺癌的临床效果及安全性。方法:回顾性分析2013年1月—2016年6月在本院乳腺外科治疗的100例晚期乳腺癌患者。所有患者均服用威麦宁胶囊,一次6~8粒,3次/d。卡培他滨1250 mg/m2,分2次口服,d1~d14,治疗两周,停药1周,21 d为1个治疗周期,连续治疗2个周期以上。观察患者的治疗周期、无进展生存期(PFS)、总体生存期(OS)以及药物不良反应。结果:患者的平均治疗周期为6.5(2~12)个周期;平均治疗时间为4.5(1.4~8.4)个月;平均PFS为6.8(1.5~15.3)个月;平均OS为14.9(2.5~21.1)月。最常见的不良反应为贫血、骨髓抑制、高血压。总缓解率为80%(95%CI 1.78~5.69)。其中10例完全缓解;70例部分缓解。结论:威麦宁胶囊联合卡培他滨治疗晚期乳腺癌具有一定的疗效,耐受性高,值得在临床大力推广应用。

Objective：To observe the clinical effect and safety of Weimaining Capsule combined with capecitabine in the treat- ment of advanced breast cancer. Methods：A retrospective analysis of January 2013 to June 2016 in our hospital breastsurgerydep- artment of 100 patients with advanced breast cancer was carried out. All patients were given Weimaining Capsule,6 -8 tablets, 3 times a day, Capecitabine 1250 mg/m2 , twice a day orally, dl - d14. The continuous treatment lasted for 2 weeks and then stopping the administration for 1 week,21 d for a treatment cycle, continuous treatment for more than 2 cycles. The progression -free survival （PFS） ,overall survival （OS） and adverse drug reactions were observed. Results：The average treatment cycle was 6.5 （2 - 12）. The average treatment time was 4.5 （ 1.4 - 8.4） months. The average PFS was 6.8 （ 1.5 - 15.3） months. The aver- age OS was 14.9 （2.5 - 21.1 ） months. The most common adverse reactions are anemia, myelosuppressionand hypertension. The overall response rate was 80% （95% CI 1.78 -5.69）. there were 10 cases completed relievered and 70 cases partially relievered. Conclusion ： Weimaining Capsule combined with capecitabine in the treatment of advanced breast cancer has a certain effect and high tolerance. It is worth to promote the clinical application.